With EMA re­view in progress, No­var­tis un­veils more pos­i­tive da­ta on asth­ma ther­a­py

Hav­ing made its mar­ket­ing pitch to the EU reg­u­la­tor, No­var­tis on Thurs­day un­veiled pos­i­tive piv­otal study da­ta sup­port­ing the use of its in­haled asth­ma treat­ment.

The ther­a­py, QMF149, con­sists of the long-act­ing be­ta-ag­o­nist, or LA­BA, called in­da­caterol ac­etate and the cor­ti­cos­teroid mometa­sone furoate. In the 2,216-pa­tient, 52-week PAL­LA­DI­UM study, asth­ma pa­tients ei­ther re­ceived a medi­um or high dose of the No­var­tis ther­a­py (150/160 μg; 150/320 μg) or mometa­sone furoate (MF) alone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER